Haemodynamic and metabolic effects of carbenoxolone in normal subjects and patients with renal impairment.

Publisher: Informa Healthcare Country of Publication: England NLM ID: 9305929 Publication Model: Print Cited Medium: Print ISSN: 1064-1963 (Print) Linking ISSN: 10641963 NLM ISO Abbreviation: Clin Exp Hypertens Subsets: MEDLINE

Publication: London : Informa Healthcare
Original Publication: New York, N.Y. : Marcel Dekker, Inc., c1993-

Carbenoxolone/*pharmacology ; Hemodynamics/*physiology ; Kidney/*metabolism ; Kidney/*physiology ; Kidney Diseases/*metabolism ; Kidney Diseases/*physiopathology; 11-beta-Hydroxysteroid Dehydrogenases ; Adult ; Aldosterone/blood ; Blood Vessels/drug effects ; Blood Vessels/physiology ; Body Weight/drug effects ; Body Weight/physiology ; Chlorides/blood ; Creatinine/blood ; Female ; Hemodynamics/drug effects ; Humans ; Hydroxysteroid Dehydrogenases/deficiency ; Hydroxysteroid Dehydrogenases/metabolism ; Hydroxysteroid Dehydrogenases/physiology ; Kidney/drug effects ; Male ; Potassium/blood ; Renin/blood ; Sodium/urine

Carbenoxolone inhibits the enzyme complex 11 beta-hydroxysteroid dehydrogenase. Functional deficiency of this complex might contribute to the hypertension of renal parenchymal disease. We have compared the effects of carbenoxolone (300 mg/day for 5 days) in six normal subjects and seven patients with renal disease. Patients with renal disease had higher blood pressure, plasma creatinine concentration (0.15 +/- 0.01 mmol/L cf. 0.09 +/- 0.01 mmol/L) and urine protein excretion than normals. In normal subjects carbenoxolone increased body weight and plasma chloride and decreased initial urine sodium excretion, packed cell volume, plasma albumin, renin and aldosterone concentrations. In patients with renal disease, carbenoxolone also produced these effects, but in addition significantly increased systolic, (129 +/- 3 to 135 +/- 5 mm Hg) mean (97 +/- 3 to 101 +/- 3 mm Hg) and diastolic blood pressure (81 +/- 3 to 85 +/- 2 mm Hg) and lowered plasma potassium (4.1 +/- 0.1 to 3.8 +/- 0.1 mmol/L) and urine sodium:potassium ratio (1.57 +/- 0.22 to 2.60 +/- 0.54). These results are consistent with the notion that partial deficiency of 11 beta-hydroxysteroid dehydrogenase contributes to the hypertension of renal parenchymal disease.

0 (Chlorides)
4964P6T9RB (Aldosterone)
9NEZ333N27 (Sodium)
AYI8EX34EU (Creatinine)
EC 1.1.- (Hydroxysteroid Dehydrogenases)
EC 1.1.1.146 (11-beta-Hydroxysteroid Dehydrogenases)
EC 3.4.23.15 (Renin)
MM6384NG73 (Carbenoxolone)
RWP5GA015D (Potassium)

Date Created: 19940701 Date Completed: 19941109 Latest Revision: 20191101

20221213

10.3109/10641969409067955

7920454